{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:17:34Z","timestamp":1790842654863,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The inclusion of mutation status improved risk stratification for newly diagnosed patients with chronic myelomonocytic leukemia (CMML). Stem cell transplantation is a potentially curative treatment option, and patient selection is critical because of relevant transplant-related morbidity and mortality. We aimed to evaluate the impact of mutation status together with clinical presentations on posttransplant outcome. Our study included 240 patients with a median follow-up of 5.5 years. A significant association with worse survival was identified for the presence of mutations in ASXL1 and\/or NRAS. In multivariable analysis, ASXL1- and\/or NRAS-mutated genotype (hazard ratio [HR], 1.63), marrow blasts &amp;gt;2% (HR, 1.70), and increasing comorbidity index (continuous HR, 1.16) were independently associated with worse survival. A prognostic score (CMML transplant score) was developed, and the following points were assigned: 4 points for an ASXL1- and\/or NRAS-mutated genotype or blasts &amp;gt;2% and 1 point each for an increase of 1 in the comorbidity index. The CMML transplant score (range, 0-20) was predictive of survival and nonrelapse mortality (P &amp;lt; .001 for both). Up to 5 risk groups were identified, showing 5-year survival of 81% for a score of 0 to 1, 49% for a score of 2 to 4, 43% for a score of 5 to 7, 31% for a score of 8 to 10, and 19% for a score &amp;gt;10. The score retained performance after validation (concordance index, 0.68) and good accuracy after calibration. Predictions were superior compared with existing scores designed for the nontransplant setting, which resulted in significant risk reclassification. This CMML transplant score, which incorporated mutation and clinical information, was prognostic in patients specifically undergoing transplantation and may facilitate personalized counseling.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003600","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:36:30Z","timestamp":1616513790000},"page":"1760-1769","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Badbaran","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich W.","family":"Beelen","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Salit","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rautenberg","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, Medical Faculty Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center\u2013University of Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Radujkovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Panagiota","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6615-7540","authenticated-orcid":false,"given":"Rashit","family":"Bogdanov","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-0412","authenticated-orcid":false,"given":"Maximilian","family":"Christopeit","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Nibourel","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Regional Universitaire Lille, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Luft","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koldehoff","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Corsten","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Medical Center\u2013University of Freiburg, Freiburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Clinical Immunology, Medical Faculty Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-9876","authenticated-orcid":false,"given":"Marie","family":"Robin","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"issue":"20","key":"2021032315362124200_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2021032315362124200_B2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"2021032315362124200_B3","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjh.15819","article-title":"Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia","volume":"185","author":"Kr\u00f6ger","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"2021032315362124200_B4","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"HemaSphere"},{"issue":"14","key":"2021032315362124200_B5","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2021032315362124200_B6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"Santini","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2021032315362124200_B7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kr\u00f6ger","year":"2002","journal-title":"Br J Haematol"},{"issue":"13","key":"2021032315362124200_B8","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2021032315362124200_B9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11899-017-0416-8","article-title":"Models of prognostication in chronic myelomonocytic leukemia","volume":"12","author":"Onida","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"3","key":"2021032315362124200_B10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3324\/haematol.2019.240853","article-title":"Are next-generation sequencing results knocking on Heaven\u2019s door for transplantation planning in chronic myelomonocytic leukemia?","volume":"105","author":"Sanz","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2021032315362124200_B11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2021032315362124200_B12","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2021032315362124200_B13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"15","key":"2021032315362124200_B14","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2021032315362124200_B15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2021032315362124200_B16","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"2021032315362124200_B17","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2021032315362124200_B18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s00277-017-3027-5","article-title":"Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation","volume":"96","author":"Heuser","year":"2017","journal-title":"Ann Hematol"},{"issue":"8","key":"2021032315362124200_B19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/14737140.2020.1796644","article-title":"Improving the accuracy of prognostication in chronic myelomonocytic leukemia","volume":"20","author":"Kaivers","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"2021032315362124200_B20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/sim.4780050306","article-title":"Censoring distributions as a measure of follow-up in survival analysis","volume":"5","author":"Korn","year":"1986","journal-title":"Stat Med"},{"issue":"3","key":"2021032315362124200_B21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"4","key":"2021032315362124200_B22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"issue":"8","key":"2021032315362124200_B23","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2021032315362124200_B24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","article-title":"Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2021032315362124200_B25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbmt.2017.01.078","article-title":"Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia","volume":"23","author":"Liu","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2021032315362124200_B26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021032315362124200_B27","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"issue":"20","key":"2021032315362124200_B28","first-page":"30661","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"S1083-8791","author":"Gagelmann","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2021032315362124200_B29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41375-019-0690-7","article-title":"Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients","volume":"34","author":"Coltro","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2021032315362124200_B30","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.18632\/oncotarget.23882","article-title":"Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"9","author":"Montalban-Bravo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"2021032315362124200_B31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jama.1996.03530260066035","article-title":"Patient-centered medicine. A professional evolution","volume":"275","author":"Laine","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"2021032315362124200_B32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.2020.1230","article-title":"Validation and utility testing of clinical prediction models: time to change the approach","volume":"324","author":"Adibi","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"2021032315362124200_B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2015.11.004","article-title":"Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia?","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021032315362124200_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123941","article-title":"Effects of the therapeutic armamentarium on survival and time to next treatment in CMML subtypes: an international analysis of 950 cases coordinated by the AGMT study group [abstract]","volume":"134","author":"Pleyer","year":"2019","journal-title":"Blood"},{"key":"2021032315362124200_B35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-138680","article-title":"Decitabine versus hydroxyurea for advanced proliferative CMML: results of the Emsco randomized phase 3 Dacota trial","volume":"136","author":"Itzykson","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2021032315362124200_B36","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.3324\/haematol.2016.162909","article-title":"Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Woo","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"2021032315362124200_B37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"29","key":"2021032315362124200_B38","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1760\/1803377\/advancesadv2020003600.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/6\/1760\/1803377\/advancesadv2020003600.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T15:36:54Z","timestamp":1616513814000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/6\/1760\/475551\/A-prognostic-score-including-mutation-profile-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003600","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}